Market Spotlight: Acne
Market Spotlight: Acne
$1,318.00
This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were approximately 623.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.
- Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.
- The majority of industry-sponsored drugs in active clinical development for acne are in Phase II. Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
- The only high-impact upcoming event in the acne space is topline Phase II trial results for LUT014. The overall likelihood of approval of a Phase I dermatology-general asset is 20.2%, and the average probability a drug advances from Phase III is 68.5%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 8.8 years in the overall dermatology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for acne have been in the early and midphases of development, with 51% of trials in Phase I–II, and 49% in Phase III–IV.
- The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
- GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Topical therapy
9 Systemic therapy
10 Physical treatments
11 EPIDEMIOLOGY
14 MARKETED DRUGS
20 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 BX001 for Acne (October 18, 2021)
27 IDP-126 for Acne (April 22, 2021)
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 US FDA GMP Warnings To OTC Firms In China, South Korea
31 Teva Leapfrogs Taro With Authorized Generic Epiduo Forte Launch
31 Upsher-Smith Adds Absorica Alternatives
32 Sol-Gel Celebrates Twyneo Approval
32 Teva Launches First Generic Of Sun’s Absorica In US
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 More Skin In The Game: Taro Acquires Alchemee For $90m
34 Journey Medical Acquires Molecule Stabilizing Platform From VYNE
34 Sanofi Adds To Vaccine Pipeline With Origimm Acquisition
35 Upsher-Smith Enters Into An Agreement With Mayne Pharma
35 Sun Strikes Deal For Clascoterone In US And Canada
36 REVENUE OPPORTUNITY
38 CLINICAL TRIAL LANDSCAPE
39 Sponsors by status
40 Sponsors by phase
41 Recent Events
43 BIBLIOGRAPHY
44 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of acne, 2019–28
20 Figure 2: Overview of pipeline drugs for acne in the US
20 Figure 3: Pipeline drugs for acne, by company
21 Figure 4: Pipeline drugs for acne, by drug type
21 Figure 5: Pipeline drugs for acne, by classification
27 Figure 6: BX001 for Acne (October 18, 2021): Phase II – Mild/Moderate Acne (Cosmetic)
29 Figure 7: IDP-126 for Acne (April 22, 2021): Phase III – Study 302
30 Figure 8: Key upcoming events in acne
33 Figure 9: Probability of success in the dermatology-general pipeline
38 Figure 10: Clinical trials in acne
38 Figure 11: Top 10 drugs for clinical trials in acne
39 Figure 12: Top 10 companies for clinical trials in acne
39 Figure 13: Trial locations in acne
40 Figure 14: Acne trials status
41 Figure 15: Acne trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of acne, 2019–28
15 Table 2: Marketed drugs for acne
22 Table 3: Pipeline drugs for acne in the US
26 Table 4: BX001 for Acne (October 18, 2021)
28 Table 5: IDP-126 for Acne (April 22, 2021)
36 Table 6: Historical global sales, by drug ($m), 2017–21
37 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Irritable Bowel Syndrome (IBS) 
Sign up to the